NeoPharm (A092730) Stock Overview
Engages in the manufacturing and sale of skin care products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for A092730 from our risk checks.
A092730 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
NeoPharm CO., LTD. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩19,990.00 |
| 52 Week High | ₩22,650.00 |
| 52 Week Low | ₩11,300.00 |
| Beta | 0.54 |
| 1 Month Change | 6.50% |
| 3 Month Change | 9.96% |
| 1 Year Change | 69.26% |
| 3 Year Change | 119.67% |
| 5 Year Change | 23.40% |
| Change since IPO | 381.24% |
Recent News & Updates
Recent updates
NeoPharm (KOSDAQ:092730) Hasn't Managed To Accelerate Its Returns
Jan 22
NeoPharm CO., LTD.'s (KOSDAQ:092730) 37% Price Boost Is Out Of Tune With Earnings
Jul 23We Think That There Are Some Issues For NeoPharm (KOSDAQ:092730) Beyond Its Promising Earnings
Nov 20The Returns On Capital At NeoPharm (KOSDAQ:092730) Don't Inspire Confidence
Nov 13NeoPharm CO., LTD.'s (KOSDAQ:092730) Earnings Are Not Doing Enough For Some Investors
Sep 13NeoPharm (KOSDAQ:092730) Will Want To Turn Around Its Return Trends
Aug 07NeoPharm CO., LTD. (KOSDAQ:092730) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected
Jun 13Benign Growth For NeoPharm CO., LTD. (KOSDAQ:092730) Underpins Its Share Price
Apr 24NeoPharm's (KOSDAQ:092730) Earnings Are Weaker Than They Seem
Mar 25Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?
Mar 28What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?
Mar 15How Much Did NeoPharm's(KOSDAQ:092730) Shareholders Earn From Share Price Movements Over The Last Three Years?
Mar 02We're Watching These Trends At NeoPharm (KOSDAQ:092730)
Feb 18We're Not So Sure You Should Rely on NeoPharm's (KOSDAQ:092730) Statutory Earnings
Feb 08
NeoPharm CO., LTD. (KOSDAQ:092730) Has Got What It Takes To Be An Attractive Dividend Stock
Jan 26An Intrinsic Calculation For NeoPharm CO., LTD. (KOSDAQ:092730) Suggests It's 31% Undervalued
Jan 15Will Weakness in NeoPharm CO., LTD.'s (KOSDAQ:092730) Stock Prove Temporary Given Strong Fundamentals?
Jan 04NeoPharm CO., LTD. (KOSDAQ:092730) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
Dec 24What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?
Dec 15Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?
Dec 04Would Shareholders Who Purchased NeoPharm's (KOSDAQ:092730) Stock Year Be Happy With The Share price Today?
Nov 23Shareholder Returns
| A092730 | KR Personal Products | KR Market | |
|---|---|---|---|
| 7D | 0.7% | 0.5% | 5.3% |
| 1Y | 69.3% | 46.4% | 109.3% |
Return vs Industry: A092730 exceeded the KR Personal Products industry which returned 46.4% over the past year.
Return vs Market: A092730 underperformed the KR Market which returned 109.3% over the past year.
Price Volatility
| A092730 volatility | |
|---|---|
| A092730 Average Weekly Movement | 5.9% |
| Personal Products Industry Average Movement | 5.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in KR Market | 13.2% |
| 10% least volatile stocks in KR Market | 2.9% |
Stable Share Price: A092730 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A092730's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 178 | Byeong-Deog Park | www.neopharm.co.kr |
NeoPharm CO., LTD. engages in the manufacturing and sale of skin care products in South Korea. The company provides Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand name; sensitive, dry, oily, or trouble-prone skin care products under the ZEROID brand; body moisturizers under the Derma-B brand name; sport care products under the MISSION ATHELETCARE brand; and dermArtlogy, a 1:1 consulting cosmetic brand.
NeoPharm CO., LTD. Fundamentals Summary
| A092730 fundamental statistics | |
|---|---|
| Market cap | ₩312.67b |
| Earnings (TTM) | ₩27.80b |
| Revenue (TTM) | ₩129.81b |
Is A092730 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A092730 income statement (TTM) | |
|---|---|
| Revenue | ₩129.81b |
| Cost of Revenue | ₩43.89b |
| Gross Profit | ₩85.92b |
| Other Expenses | ₩58.12b |
| Earnings | ₩27.80b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.78k |
| Gross Margin | 66.19% |
| Net Profit Margin | 21.41% |
| Debt/Equity Ratio | 0% |
How did A092730 perform over the long term?
See historical performance and comparisonDividends
Does A092730 pay a reliable dividends?
See A092730 dividend history and benchmarks| NeoPharm dividend dates | |
|---|---|
| Ex Dividend Date | Dec 29 2025 |
| Dividend Pay Date | Apr 09 2026 |
| Days until Ex dividend | 57 days |
| Days until Dividend pay date | 44 days |
Does A092730 pay a reliable dividends?
See A092730 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/23 18:30 |
| End of Day Share Price | 2026/02/23 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NeoPharm CO., LTD. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jiseon An | DAOL Investment & Securities Co., Ltd. |
| Byung-Ki Kim | Hanwha Investment & Securities Co., Ltd. |
| Seung Wook Lee | Hanwha Investment & Securities Co., Ltd. |